Louis Sloan

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

David A. Margolis, Juan González‐García, Hans-Jürgen Stellbrink et al. · The Lancet · 2017 · 492 citations

Treatment And Prevention, Medicine, Phase 2B +8

Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment

Kimberly Y. Smith, Parul Patel, Derek M. Fine et al. · AIDS · 2009 · 217 citations

Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults

Sherene Min, Louis Sloan, Edwin DeJesus et al. · AIDS · 2011 · 212 citations

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial

Jean‐Michel Molina, Kathleen Squires, Paul E. Sax et al. · The Lancet HIV · 2018 · 140 citations

Treatment And Prevention, Antiviral Drug Development, Clinical Trials +7

Simplification of Antiretroviral Therapy to a Single-Tablet Regimen Consisting of Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate Versus Unmodified Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients

Edwin DeJesus, Benjamin Young, Javier O Morales-Ramirez et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2009 · 133 citations